CD73 and CD39: Predictive and Prognostic Biomarkers

Tumor TypeFindings# of PatientsStudy Author
Negatively prognosticNSCLC (stage I-III)High CD73 expression was an independent risk factor for decreased overall survival and dereased recurrence-free survival642Inoue, et al. [54]
Prostate CancerCD73 expression in normal tissue was a negative prognostic factor for prostate-infiltrating CD8(+) cells. However, high expression of CD73 in tumor stroma was associated with longer recurrence-free survival285Leclerc, et al. [55]
Breast Cancer (Triple Negative)CD73 expression is associated with anthracycline resistance and poor prognosis6000Loi, et al. [56]
High-Grade Serous Ovarian CancerHigh levels of CD73 are associated with shorter disease-free survival and overall survival1581Gaudreau, et al. [57]
Colorectal Cancer (stage I-IV)High expression of CD73 predicts poor survival223Wu, et al. [58]
Gastric Cancer (stage I-IV)High expression CD73 is associated with lowered overall survival68Lu, et al. [65]
Melanoma (Stage IV)High soluble CD73 activity was associated with poor overall survival and poor progression-free survival37Morello, et al. [59]
Head and Neck Cancer (stage I-IV)High levels of CD73 are associated with reduced overall survival162Ren, et al. [60]
Renal Cell Cancer (Stage I-IV)High expression of CD73 is associated with disease progression and shortened overall survival189Yu, et al. [2]
Positively prognosticNonmuscle-Invasive Urothelial Bladder CancerHigh CD73 iactivity was associated with favorable clinicopathological features. Furthermore, predicts better outcome in the subgroup of pTa and pT1 tumors.174Wettstein, et al. [61]
Breast Cancer (stage I-III)CD73 expression strongly correlated with longer disease-free survival and overall survival136Supernat, et al. [62]
Endometrial Carcinoma (endometrial endometrioid carcinomas, Grade 1–3) and nonendometrioid uterine papillary serous carcinomasCD73 is markedly downregulated in poorly differentiated and advanced-stage disease compared with levels in normal endometrium and low-grade tumors49Bowser, et al. [64]
Colorectal cancer (Stage IV)High CD73 expression was associated with longer progression free survival from cetuximab treatment in patients with KRAS-WT and KRAS-mutant tumors238Cushman, et al. [63]
Negatively prognosticGastric Cancer (stage I-IV)High CD39 expression is a predictor of poor outcome following radical resection101Cai, et al. [69]
Hepatocellular carcinomaHigh CD39 expression is an independent indicator of decreased overall suvival after radical resection324Cai, et al. [70]
Chronic lymphocytic leukemiaCD39 expression on CD4+ lymphocytes are increased in the peripheral blood of patients with CLL and correlates with advanced stage of disease62Perry, et al. [71]